A targeted IL-15 fusion protein with potent anti-tumor activity

Cancer Biology and Therapy

Volumn 16, Issue 9, 2015, Pages 1415-1421

  Chen, Siqi ^a   Huang, Qiang ^a   Liu, Jiayu ^a   Xing, Jieyu ^a   Zhang, Ning ^b   Liu, Yawei ^c   Wang, Zhong ^a   Li, Qing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c Chinese PLA   (China)

Author keywords

fusion protein; IL 15; IL 15R ; RGD; tumor immunotherapy

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; PFC 1 FUSION PROTEIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT; PFC-1 PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN TARGETING; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; METABOLISM; MOLECULARLY TARGETED THERAPY; MONONUCLEAR CELL; PATHOLOGY; PHYSIOLOGY; SECONDARY; SKIN NEOPLASMS; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS;

EID: 84941805456     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1071739     Document Type: Article

References (28)

1. M.J.Smyth, E.Cretney, M.H.Kershaw, Y.Hayakawa. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202:275-93; PMID:15546400; http://dx.doi.org/10.1111/j.0105-2896.2004.00199.x
2. T.A.Fehniger, M.A.Cooper, M.A.Caligiuri. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002; 13:169-83; PMID:11900992; http://dx.doi.org/10.1016/S1359-6101(01)00021-1
3. M.Dafne. Targeted cancer immunotherapy: mimicking physiological trans-presentation of IL-15. Oncoimmunology 2012; 1:1213-4; PMID:23170284; http://dx.doi.org/10.4161/onci.20824
4. S.Dubois, J.Mariner, T.A.Waldmann, Y.Tagaya. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002; 17:537-47; PMID:12433361; http://dx.doi.org/10.1016/S1074-7613(02)00429-6
5. Y.Rochman, R.Spolski, W.J.Leonard. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9:480-90; PMID:19543225; http://dx.doi.org/10.1038/nri2580
6. V.Kermer, V.Baum, N.Hornig, R.E.Kontermann, D.Muller. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site. Mol Cancer Ther 2012; 11:1279-88; PMID:22491823; http://dx.doi.org/10.1158/1535-7163.MCT-12-0019
7. M.A.Cheever. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222:357-68; PMID:18364014; http://dx.doi.org/10.1111/j.1600-065X.2008.00604.x
8. H.Kobayashi, J.A.Carrasquillo, C.H.Paik, T.A.Waldmann, Y.Tagaya. Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Res 2000; 60:3577-83; PMID:10910071
9. A.Bessard, V.Sole, G.Bouchaud, A.Quemener, Y.Jacques. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8:2736-45; PMID:19723883; http://dx.doi.org/10.1158/1535-7163.MCT-09-0275
10. M.P.Rubinstein, M.Kovar, J.F.Purton, J.H.Cho, O.Boyman, C.D.Surh, J.Sprent. Converting IL-15 to a superagonist by binding to soluble IL-15R{α}. Proc Natl Acad Sci USA 2006; 103:9166-71; PMID:16757567; http://dx.doi.org/10.1073/pnas.0600240103
11. T.A.Stoklasek, K.S.Schluns, L.Lefrançois. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177:6072-80; PMID:17056533; http://dx.doi.org/10.4049/jimmunol.177.9.6072
12. S.Dubois, H.J.Patel, M.Zhang, T.A.Waldmann, J.R.Muller. Preassociation of IL-15 with IL-15R α-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 2008; 180:2099-106; PMID:18250415; http://dx.doi.org/10.4049/jimmunol.180.4.2099
13. T.Kukita, N.Arima, K.Matsushita, K.Arimura, H.Ohtsubo, Y.Sakaki, H.Fujiwara, A.Ozaki, T.Matsumoto, C.Tei. Autocrine and/or paracrine growth of adult T-cell leukaemia tumour cells by interleukin 15. Br J Haematol 2002; 119:467-74; PMID:12406087; http://dx.doi.org/10.1046/j.1365-2141.2002.03813.x
14. Y.L.Yu, C.W.Wei, Y.L.Chen, M.H.Chen, G.T.Yiang. Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression. Int J Oncol 2010; 36:365-70; PMID:20043070; http://dx.doi.org/10.3892/ijo_00000603
15. M.Vera, N.Razquin, J.Prieto, I.Melero, P.Fortes, G.Gonzalez-Aseguinolaza. Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. Mol Ther 2005; 12:950-9; PMID:15921960; http://dx.doi.org/10.1016/j.ymthe.2005.03.030
16. M.Kaspar, E.Trachsel, D.Neri. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007; 67:4940-8; PMID:17510424; http://dx.doi.org/10.1158/0008-5472.CAN-07-0283
17. D.C.Roopenian, S.Akilesh. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155
18. D.M.Czajkowsky, J.Hu, Z.Shao, R.J.Pleass. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012; 4:1015-28; PMID:22837174; http://dx.doi.org/10.1002/emmm.201201379
19. R.E.Kontermann. Antibody-cytokine fusion proteins. Arch Biochem Biophys 2012; 526:194-205; PMID:22445675; http://dx.doi.org/10.1016/j.abb.2012.03.001
20. M.S.Aguzzi, P.Fortugno, C.Giampietri, G.Ragone, M.C.Capogrossi, A.Facchiano. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer 2010; 9:84; PMID:20412563; http://dx.doi.org/10.1186/1476-4598-9-84
21. H.Gao, Y.Xiong, S.Zhang, Z.Yang, S.Cao, X.Jiang. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm 2014; 11:1042-52; PMID:24521297; http://dx.doi.org/10.1021/mp400751g
22. K.Chen, X.Chen. Integrin targeted delivery of chemotherapeutics. Theranostics 2011; 1:189-200; PMID:21547159; http://dx.doi.org/10.7150/thno/v01p0189
23. F.Danhier, A.Le Breton, V.Preat. RGD-based strategies to target α(v) β(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012; 9:2961-73; PMID:22967287; http://dx.doi.org/10.1021/mp3002733
24. X.Zhu, W.D.Marcus, W.Xu, H.I.Lee, K.Han, J.O.Egan, J.L.Yovandich, P.R.Rhode, H.C.Wong. Novel human interleukin-15 agonists. J Immunol 2009; 183:3598-607; PMID:19710453; http://dx.doi.org/10.4049/jimmunol.0901244
25. K.Xiao, Y.Li, J.S.Lee, A.M.Gonik, T.Dong, G.Fung, E.Sanchez, L.Xing, H.R.Cheng, J.Luo, et al. “OA02” peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res 2012; 72:2100-10; PMID:22396491; http://dx.doi.org/10.1158/0008-5472.CAN-11-3883
26. E.Mortier, T.Woo, R.Advincula, S.Gozalo, A.Ma. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 2008; 205:1213-25; PMID:18458113; http://dx.doi.org/10.1084/jem.20071913
27. G.Bouchaud, L.Garrigue-Antar, V.Sole, A.Quemener, Y.Boublik, E.Mortier, H.Perdreau, Y.Jacques, A.Plet. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J Mol Biol 2008; 382:1-12; PMID:18656487; http://dx.doi.org/10.1016/j.jmb.2008.07.019
28. Z.Wu, Y.Xu. IL-15R α-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation. J Mol Cell Biol 2010; 2:217-22; PMID:20671116; http://dx.doi.org/10.1093/jmcb/mjq012